CREO clearly has a huge opportunity in a multi £billion market. The Group also appears to have made plenty of progress since arriving on AIM in December 2016 at a share price of 76p and market capitalisation of a modest £61m, reflected in the 200% rise in share price to 228p.
Creo Medical was founded in 2003 as MicroOncology Ltd by the Group’s current Chief Technology Officer, Prof Chris Hancock, initially to target the treatment of cancers through use of high frequency microwave energy and dynamic matching techniques.
The business strategy subsequently evolved to develop medical devices with a wider application and was subsequently re-branded as Creo Medical in 2010 to reflect this.
The team was also expanded to introduce additional experience in the design, manufacture, production and commercialisation of electrosurgical medical devices.
Chief Executive Craig Gulliford is a founding angel investor in CREO and joined the company as CEO in 2012. Craig qualified with an MSc in Electronic Engineering from the…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY